TO THE EDITOR
The MDR1 gene encodes the P-glycoprotein (P-gp), an energydependent transmembrane efflux pump for a variety of unrelated, hydrophobic amphipathic drugs. 1 It reduces cytoplasmic drug levels and its cytotoxic effects, thus leading to multidrug resistance (MDR). P-gp is expressed by different normal cells, including the hematopoietic tissue. In hematopoietic stem cells, P-gp is physiologically related to cell protection against toxic substances and metabolites. 1, 2 Moreover, it has the ability to cause the MDR phenotype in leukemic cells.
3 P-gp expression is a poor prognostic factor in acute leukemia, particularly acute myeloid leukemia (AML), and is mainly associated with a more immature phenotype and the expression of the CD34 antigen. 4 The prevalence of P-gp expression in AML progressively increases with age, 5 being very high among elderly patients, but the reason for this finding is not completely understood. 6 The aim of the present study was to evaluate age-related changes of P-gp function in normal human bone marrow stem cells. Bone marrow samples from 46 individuals were collected (36 donors for transplant, four subjects submitted to thoracotomy for myocardial revascularization who were taking neither verapamil nor digoxin, four with iron-deficiency anemia, one recovered from megaloblastic anemia, and one with immune thrombocytopenic purpura). These subjects were divided into four age groups: 8-19 years (n ¼ 12), 20-35 years (n ¼ 17), 35-50 years (n ¼ 7), and 50-82 years (n ¼ 10). Subjects came from the same geographic region (Southeastern Brazil) and samples were obtained after informed consent. For individuals submitted to myocardial revascularization, bone marrow fragments were taken immediately after thoracotomy and rinsed with phosphate-buffered saline. All other samples were obtained by posterior iliac crest aspiration in EDTA-containing tubes and mononuclear cells separated by density gradient centrifugation. CD34+ cells were purified from bone marrow mononuclear cells by indirect magnetic labeling (Miltenyi Biotec, Auburn, CA, USA), as previously described.
7 P-gp activity was determined by efflux of Rh123 (Sigma), a fluorescent dye that is a substrate for P-gp, as previously described, 7 and analyzed with a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). The Rh123 efflux index was calculated based on the ratio of mean fluorescence intensity for Rh123 in Rh123+verapamil/Rh123. The Spearman nonparametric correlation test followed by linear regression analysis was employed to assess P-gp function changes as a function of age. The Kruskal-Wallis nonparametric test followed by Dunn's multiple comparison test was used for differences among age groups. A Pvalue of o0.05 was considered to be statistically significant.
A progressive increase in P-gp activity was observed as a function of age in bone marrow CD34+CD45+ stem cells (Spearman r ¼ 0.36; P ¼ 0.01; Figure 1 ). P-gp function was lower in the 8-19 year group (1.52, 1.44-1.99), progressively increasing to 2.29 (2.05-2.48; Po0.05) in the 20-35 year group, and reaching the highest values in the 35-49 year group (2.68, 2.12-3.46; Po0.01 in comparison with the younger age group). In the age group older than 50 years, P-gp function (2.18, 1.81-2.60) was not statistically different from the other age groups, as illustrated in Figure 2 .
Our results on age-associated changes of P-gp function in hematopoietic stem cells correlate with those of Leith et al. 5 In a comprehensive study, these authors 5 evaluated the prevalence of Pgp expression and function in 352 newly diagnosed AML patients (median age, 44 years; range, 17-69 years), divided into three age groups and found a progressive increase in P-gp expression with age. P-gp expression was observed in 17% of AML patients younger than 35 years, in 27% of patients aging between 35 and 49 years, and in 39% of patients older than 50 years. In our study, we analyzed the P-gp function in the same age groups and in an additional younger group (8-19 years old), and found that P-gp activity also increases with age in normal CD34+ cells (r ¼ 0.36; P ¼ 0.01). However, P-gp function increases up to the 35-50 year group, remaining in the same range thereafter. Taken together, these data support, at least in part, the view that the increase with age in the prevalence of P-gp-mediated MDR phenotype in AML may be related to the age-associated changes in P-gp expression in normal hematopoietic stem cells. However, the very high frequency of P-gp expression (71%) observed by Leith et al 6 in the elderly AML patients (58-88 years) cannot be explained by our findings. In this particular patient group, the biology of leukemic cells is distinct and myeloblasts frequently express a more immature immunophenotype. However, P-gp expression in blast cells of elderly AML patients is not influenced by maturation-associated immunophenotype. 4 Other environmental or genetic mechanism(s) may be involved in the P-gp upregulation in elderly AML patients. Although MDR1 gene polymorphisms determine P-gp expression in peripheral blood lymphocytes, these mutations do not influence P-gp function in bone marrow hematopoietic stem cells, 7 and might not play a role in P-gp expression of leukemic blasts. On the other hand, the hypomethylation status of CpG sites at the promoter region of the MDR1 gene seems to be associated with P-gp expression in AML. 8 In conclusion, hematopoietic stem cells showed increased P-gp activity as a function of age, and these changes might contribute to the increase in the prevalence of P-gp expression in leukemic myeloid blast cells with age. 
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Figure 2
Variation of P-gp function in CD34+ stem cells with age. P-gp function is expressed as the ratio of rhodamine 123 mean fluorescence in the presence and in the absence of verapamil (rhodamine 123 efflux index). P-gp activity was low in the 8-19 year group and progressively increased with age up to the 35-50 year group. 
TO THE EDITOR
Fibroblast growth factor-2 (FGF-2) is the prototypic member of the FGF family of growth factors. In the adult organism, FGF-2 coregulates a number of biological processes, including hematopoiesis. Recently, elevated FGF-2 levels in blood were reported in patients suffering from a number of hematopoietic malignancies, for example hairy cell leukemia, chronic myeloid leukemia, chronic lymphoid leukemia and non-Hodgkin's lymphoma. [1] [2] [3] These findings suggest that a dysregulation of FGF-2 synthesis may be a common event in the development of hematopoietic neoplasm. There are at least three ways whereby FGF-2 could contribute to the pathogenesis of leukemia and lymphoma. First, FGF-2 is a potent activator of endothelial proliferation and can thus stimulate bone marrow angiogenesis. Second, FGF-2 promotes stromal fibroblast proliferation and extracellular matrix formation leading to excessive bone marrow fibrosis. Third, FGF-2 can directly affect neoplastic cells by acting on their high-affinity fibroblast growth factor receptors.
The aim of the present study was to extend our knowledge on the expression and action of FGF-2 in leukemia-and tumor-derived cells 4, 5 by characterizing the autocrine activity of FGF-2 in panel of leukemia and lymphoma cell lines. To this end, we used 12 model cell lines (Mono-Mac-1, NB-4, HL-60, THP-1, ML-2, HPB-ALL, U-937, Bv-173, K-562, Ramos-AW, Jurkat and Molt-4) to examine critical parameters relevant to the autocrine action of FGF-2.
Western blot (WB) analysis of intracellular FGF-2 showed that all tested cell lines express at least one molecular variant of FGF-2 protein comprising the exportable low molecular mass (LMM; 18-kDa) variant and the nuclearly localized high molecular mass (HMM; 22, 24 and 34 kDa) variants (Figure 1a) . The capability of cells to release FGF-2 was tested by incubation of conditioned cellfree media with heparin-sepharose beads. The following WB analysis of proteins bound to the heparin-sepharose revealed a strong signal for LMM FGF-2 in media conditioned by HL-60, K-562 and Molt-4 cells (Figure 1b) . This was confirmed using ELISA (Figure 1c ). Other cell lines did not release any FGF-2 into the culture media (Mono-Mac-1, NB-4, THP-1, ML-2, HPB-ALL, U-937 and Ramos-AW) or FGF-2 signal was weakly detectable (Bv-173 and Jurkat).
The expression of fibroblast growth factor receptors (FGFR-1-4) was studied by WB. Figure 2 We also asked whether exogenous FGF-2 could affect viability and/or proliferation of leukemia and lymphoma cell lines. Serumstarved cells were exposed to increasing concentrations of FGF-2 (1, 10 and 100 ng/ml) for 1, 3 and 6 days, and the changes in cell number were determined by cell counting. Simultaneously, cell death was determined by trypan blue exclusion and the metabolic activity of stimulated cells was measured using WST-1 reagent. NIH3T3 fibroblasts were used as an FGF-2-responsive control. Only three cell lines (HL-60, HPB-ALL and Molt-4) responded to FGF-2 treatment with a transient increase in their metabolic activity. Importantly, exogenous FGF-2 did not affect the viability or proliferation of any of the cell lines included in our panel (data not shown).
The expression of HMM FGF-2 has been shown to promote tumorigenesis and cell growth in low-serum conditions as well as induce radioresistance. 6 However, little is known about molecular mechanisms underlying the action of HMM FGF-2. Recently, a nuclear antiapoptotic factor named FGF-2-interacting factor (FIF) or antiapoptotic clone 11 (AAC-11) that interacts specifically with HMM FGF-2 was described. 7, 8 Having determined that the majority of studied leukemia and lymphoma cells synthesize HMM FGF-2, we examined the expression of the FIF protein in these cells through WB. Figure 4a demonstrates that all cell lines, except Mono-Mac-1 and Jurkat, abundantly synthesize FIF. Moreover, coprecipitation experiments revealed association of FGF-2 and FIF in HL-60 and K-562, suggesting intracrine activities (Figure 4b) .
We have shown that while LMM FGF-2 is synthesized by the majority of tested leukemia and lymphoma cell lines, its release is generally insufficient as only a small subset of cell lines produce LMM FGF-2 into the culture media. This finding does not confirm the previous idea that the malignant clone is the exclusive source of soluble FGF-2 found in the blood of leukemia and lymphoma patients. Rather, other FGF-2-producing cells such as bone marrow fibroblasts or endothelial cells could contribute, under disease conditions, to elevated blood FGF-2. Importantly, several cell lines displayed prerequisites to respond to the extracellular FGF-2, demonstrating that malignant cells could still be the target for FGF-2 paracrine action in blood. Our next experiments, however, showed that cell proliferation is not the parameter modulated in studied cell lines by exogenous FGF-2, leaving the nature of cellular response to FGF-2 unclear. In this context, expression and release of FGF-2, FGFR outfit and FGF-2-induced phosphorylation of ERK 1/2 together highlight HL-60, K-562 and Molt-4 cell lines as valuable models for further studies. 
